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NSAIDs was not influenced by any QoL variables. Co-
morbidity, severity of GI symptoms (GIS), and the MCS
all had a significant impact on GI medication use. In mul-
tivariate analyses, MCS, HAQ, satisfaction with health
and comorbidity were independent predictors of health-
care resource use. Results have clinical relevance, as, for
example, a 1-unit change in HAQ predicts one additional
visit per 6 months. 
CONCLUSIONS: QoL measures and health rating scales
both can be used to predict healthcare resource use. Men-
tal health is important in predicting healthcare resource
use among patients with arthritis.
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OBJECTIVE: The objective was to investigate the com-
pliance and expenditure impact of pharmacist’s cognitive
services (i.e., services that require clinical skills, such as
patient education).
METHODS: Data came from the Cognitive Activities and
Reimbursement Effectiveness Project (CARE), and from
Washington State Medicaid. There were three groups of
pharmacies: a group that was paid to provide cognitive
services (n  110), a group that was not paid but did doc-
ument the provision of cognitive service (n  90), and a
control group (n  100) matched to patients in the paid
and nonpaid groups. Data were collected for 6 months of
both baseline and follow-up. There were 992 patients from
the paid group pharmacies, 554 from the nonpaid, and
6,021 from the control group. The outcomes of interest
were 1) medication noncompliance, 2) utilization of ser-
vices, and 3) expenditures. The analysis focused on seven
target diseases (epilepsy, depression, heart disease, throm-
bolic disease, hypertension, diabetes, and schizophrenia).
RESULTS: The paid and nonpaid groups were 31% less
likely to be noncompliant (OR  0.69; 95% CI 0.51–
0.94) than the control group. The likelihood of compli-
ance increased with increasing numbers of services per
patient. Total cost was not significantly increased (p 
0.05) for the paid or nonpaid group. There was an in-
crease in prescription cost and use for target diseases in
the paid and nonpaid group (p  0.05), but there was
also a contemporaneous trend (p  0.05) toward de-
creased cost of other components of care.
CONCLUSION: Paying for cognitive services may be cost
neutral overall, while increasing the likelihood of favorable
clinical outcomes through gains in medication compliance.
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OBJECTIVE: To determine the baseline running cost of
maintaining a patient in a general medical ward for 1 day.
METHOD: Forty-three patients (19 males, 24 females)
were retrospectively randomly selected from January
through July 1997 from medical admission lists of the fol-
lowing specialties: cardiology, neurology, rheumatology,
endocrinology, gastroenterology, infectious diseases, and
hematology. Data on patients’ demographics, medications,
clinical and laboratory investigations and procedures were
collected from patients’ files. Fixed and variable costs were
identified and costed. Fixed costs included nursing, biomed-
ical engineering, laundry, catering, cleaning, maintenance,
and administration overheads, but excluded the costs of the
hospital building per se. Among the variable costs were
professional fees, including those of physicians, clinical
pharmacists, physiotherapists, and dieticians. The average
daily running cost was calculated and comparative analysis
was made for differences between sex and age groups.
RESULTS: The average daily running cost (in US dollars)
of maintaining a patient in a general medical ward was
$202. There was no statistical difference (p  0.05) for
either sex ($196: $203, male: female) or age group ($193:
$204, (30: 30).
CONCLUSION: This study determined the daily baseline
running cost of maintaining a patient in a general medical
ward. Both fixed and variable costs were comparable for
sex and age groups, but the fixed costs were almost dou-
ble the variable costs. This was a helpful pilot study and
provided a base for further future larger studies in deter-
mining the average daily running costs of maintaining pa-
tients in general medical wards.
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OBJECTIVE: In the comparison between an innovative
treatment versus a standard reference treatment, modern
cost-effectiveness studies evaluate the survival data of the
two treatments and determine the survival gain, using a
long-term time horizon. These studies are often con-
ducted in the area of biotechnology drugs (e.g., the new-
